Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech ...
read more
AGC Biologics announced a development and manufacturing services agreement with specialty vaccine company Valneva SE to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility.
read more
AGC Chemicals now offers small-molecule API contract manufacturing services.
read more
AGC has announced the completion of its acquisition of Spain's synthetic pharmaceutical active ingredient manufacturer, Malgrat Pharma Chemicals, S.L.U. (MPC).
read more
Tuesday, January 15, 2019
AGC has entered into an agreement with Boehringer Ingelheim to acquire its subsidiary Malgrat Pharma Chemicals, S.L.U. (MPC).
read more
Tuesday, September 25, 2018
AGC will be establishing a cGMP-compatible mammalian cell culture facility at its Chiba Plant designed to take on contracts for antibody biopharmaceutical development and production
read more
AgeneBio announced that the company has received an additional $750,000 grant from the Alzheimer's Drug Discovery Foundation.
read more
Monday, December 28, 2015
Agenus Inc., an immunotherapy company developing innovative treatments for cancer, today announced that it has acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens.
read more
Friday, November 20, 2020
Agenus announced that a milestone payment of $10M from Merck has been triggered with the advancement of an ILT4 antibody, MK-4830, into a Phase 2 clinical trial.
read more
Agenus Inc., an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced acquisition of XOMA Corporation’s antibody manufacturing pilot plant and capabilities.
read more
Wednesday, November 15, 2017
Agenus announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck.
read more
Agenus announced that Merck initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration.
read more
Tuesday, January 09, 2018
Agilent Technologies has acquired Cork, Ireland-based Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits.
read more
Monday, September 30, 2024
Agilent Technologies Inc. announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and ...
read more
Agilent Technologies announced that it is breaking ground on a 15,000-square-foot expansion of the company’s logistics center in Cedar Creek, Texas.
read more